Edodekin alfa

Drug Profile

Edodekin alfa

Alternative Names: CLMF; human interleukin-12; NKSF; Recombinant human interleukin-12; rhIL-12; rHuIL-12; RO 247472; YM 01C

Latest Information Update: 04 Sep 2006

Price : $50

At a glance

  • Originator Roche; Wistar Institute
  • Developer Roche; Valeant Pharmaceuticals International
  • Class Adjuvants; Interleukins
  • Mechanism of Action Angiogenesis inhibitors; Cytokine stimulants; Immunostimulants; Interferon gamma stimulants; Interleukin stimulants; Natural killer cell stimulants; T lymphocyte stimulants; Tumour necrosis factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Asthma; Bacterial infections; Cancer; Cutaneous T cell lymphoma; Graft-versus-host disease; Hepatitis B; Hepatitis C; HIV infections; Kaposi's sarcoma; Leishmaniasis; Lymphoma; Malaria; Malignant melanoma; Non-Hodgkin's lymphoma; Renal cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 04 Sep 2006 Discontinued - Phase-I for Asthma in USA (Inhalation)
  • 04 Sep 2006 Discontinued - Phase-I for Asthma in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top